“We are 3-5 years away by shocking the world” -Arvind Krishna

|

The quote from IBM’s Chairman and CEO, Arvind Krishna, that “we are 3-5 years away by shocking the world” is a bold declaration, positioning IBM at the forefront of a technological revolution comparable to the advent of the personal computer or the internet.


The quote from IBM’s Chairman and CEO, Arvind Krishna, that “we are 3-5 years away by shocking the world” is a bold declaration, positioning IBM at the forefront of a technological revolution comparable to the advent of the personal computer or the internet.

This isn’t just corporate swagger; it reflects the accelerating progress in quantum computing—a paradigm shift that promises to unlock solutions to problems currently intractable for even the world’s most powerful supercomputers.

The 3-5 year timeline points directly to the industry’s next major milestone: achieving practical, useful “Quantum Advantage” and delivering the first generation of fault-tolerant quantum computers.

Is This Another Revolution for IBM? Will They Be the New Era again?

IBM has a history of foundational technological shifts, from the mainframe to the personal computer (PC) and the creation of fundamental software. With quantum computing, they are indeed making a significant bid for another revolution:

The IBM Approach: Enterprise and Ecosystem: IBM’s strategy is heavily focused on an enterprise-first model. They have built the IBM Quantum Network and made their quantum systems accessible via the cloud (IBM Quantum Experience/Lab). This focus on a full-stack solution—from hardware to the open-source Qiskit development framework—aims to integrate quantum computing into existing business workflows, positioning them as the reliable provider for businesses and researchers looking for early practical applications.

Who Has Better Chances? The Quantum Race

The competition for the “new Apple” or “new Microsoft” of quantum computing is intense, and the winner is far from decided, as different technological approaches carry different risks and rewards:

CompanyKey ApproachStrengthsThe Gamble
IBMSuperconducting Qubits; Full-Stack Ecosystem; Cloud AccessLeading in current qubit count (e.g., Condor 1,121 qubits), a clear roadmap for enterprise adoption, and a strong open-source community (Qiskit).Superconducting qubits require extreme refrigeration (near absolute zero) and face scaling challenges with error correction.
Google (Alphabet)Superconducting Qubits; Focus on Error CorrectionDemonstrated “quantum supremacy” and leading advancements in suppressing errors in logical qubits (e.g., Willow chip progress).Less focused on immediate enterprise deployment; a more academic/performance-driven approach.
MicrosoftTopological Qubits (Majorana Zero Modes)If successful, topological qubits are theoretically far more stable and inherently error-resistant than competitors’ qubits.This technology is the most speculative; they are betting on a complete breakthrough in a new state of matter to build the qubit.
Other Players (IonQ, Rigetti, Quantinuum)Trapped-Ion, Photonic, Quantum AnnealingTrapped-Ion (IonQ, Quantinuum) systems currently boast the highest fidelity (lowest error rate) qubits. Quantum Annealers (D-Wave) are commercially available now for specific optimization problems.IonQ/Quantinuum face scaling challenges; D-Wave is not a universal gate-based QC.

IBM’s Quantum Roadmap: The Path to “Shocking the World”

IBM’s roadmap is a direct attempt to provide measurable, scalable, and commercially useful quantum computing, moving beyond purely academic demonstrations. Their 3-5 year timeline is mapped to two critical, verifiable milestones: Quantum Advantage and Fault-Tolerant Quantum Computing.

1. The Near Term: Achieving Quantum Advantage (By 2026)

The next major goal is to demonstrate “Quantum Advantage”: proving that a quantum computer can solve a problem faster or better than the best classical supercomputer in the world. IBM is focusing on utility and complexity:

MilestoneTarget YearDescription & Significance
New Processors & ConnectivityLate 2025Introduction of the Quantum Nighthawk processor (120+ qubits) with enhanced connectivity (218 tunable couplers). This allows users to execute circuits with 30% greater complexity and up to 5,000 two-qubit gates initially.
Verified Quantum AdvantageEnd of 2026The goal is to demonstrate the first verified examples of quantum advantage in scientifically relevant domains, likely in specific simulations for quantum chemistry or materials science, using hybrid quantum-classical systems.
Fault-Tolerant Module2026Demonstration of the first functional building block of a fault-tolerant system. This is a crucial step that involves using multiple physical qubits to encode one robust logical qubit and actively correcting errors.
Scaling Qiskit2027IBM plans to continue enhancing its open-source software stack, Qiskit, by adding computational libraries for machine learning, optimization, and physical/chemical modeling, making the quantum hardware more accessible for application development.

The Quantum Revolution in Drug Discovery and Materials Science

The sector most ripe for disruption is the simulation of nature—specifically, quantum chemistry and materials science. This is where the core advantage of quantum mechanics (superposition and entanglement) is a direct computational fit.

The Classical Bottleneck

Classical supercomputers rely on approximations to solve the Schrödinger equation, which governs the behavior of electrons in molecules. The complexity of this simulation grows exponentially with the number of atoms.

For example, simulating a medium-sized molecule (around 50-60 atoms) requires more memory than there are atoms in the known universe, making accurate drug-target simulations impossible on classical machines.

The Quantum Solution

Quantum computers model these molecular systems directly. The key impacts are:

1. Accelerated Drug Design

  • Accurate Molecular Simulation: Quantum algorithms, such as the Variational Quantum Eigensolver (VQE), can precisely simulate the electronic structure of drug molecules and their targets (e.g., proteins or enzymes). This allows researchers to calculate properties like binding affinity (how strongly a drug sticks to its target) and toxicity with unprecedented accuracy.
  • Protein Folding: While extremely complex, quantum computers are theorized to help solve the protein folding problem—predicting a protein’s 3D shape from its amino acid sequence. Misfolding is linked to diseases like Alzheimer’s and Parkinson’s. Solving this would revolutionize targeted drug creation.
  • Virtual Screening: Quantum computing can rapidly search vast virtual chemical spaces (libraries containing billions of potential drug candidates) for molecules that meet specific therapeutic criteria, drastically cutting down on the time and cost of wet-lab testing.

2. Materials Science Breakthroughs

  • Superconductivity: Accurately simulating materials could lead to the discovery of room-temperature superconductors—a material science holy grail. This would revolutionize energy transmission, computing, and transportation (e.g., magnetic levitation).
  • Catalysts and Batteries: Quantum simulation can accelerate the discovery of new catalysts for industrial processes (e.g., making fertilizer more efficiently or developing advanced carbon capture technologies) and designing new battery electrolytes with higher energy density and faster charging times.

The Role of Qiskit (IBM’s Software)

IBM’s Qiskit is the open-source software framework central to this effort. It provides the tools and algorithms (like VQE) that researchers need to write quantum programs. IBM’s collaborations with biotech firms like Algorithmiq focus on developing techniques within Qiskit to mitigate errors on current noisy devices, making them immediately useful for small, critical parts of drug discovery workflows.

In short, when Arvind Krishna talks about “shocking the world,” he’s pointing to the moment (2026-2029) when quantum simulation moves from a theoretical possibility to an industrial tool that generates verifiable, high-value commercial results in chemistry, medicine, and engineering.